Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Moderna

The race is on for a coronavirus cure as the pandemic sickens millions. These three vaccine stocks are in the investing spotlight right now.

The Top 3 Coronavirus Vaccine Stocks to Consider Right Now

Inovio Pharmaceuticals Inc. INO, -0.07% said Thursday it has received another grant from the Coalition for Epidemic Preparedness Innovations, or CEPI, an Oslo-based organization, to help it expend manufacturing of its COVID-19 vaccine candidate.

Inovio to expand manufacturing of COVID-19 vaccine candidate with new CEPI grant

Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) announced the completion of enrollment in the Phase 1 trial of its COVID-19 DNA vaccine INO-4800 and positive Phase 1/2a data for its MERS coronavirus vaccine INO-4700 on Tuesday.

Inovio Analysts Project About 24% Upside Potential Amid Optimism On Coronavirus DNA Vaccine

Biotechnology company Inovio currently has no approved products on the market and INO stock's recent run up in price is based on a potential COVID-19 vaccine that may be months or even years away
The post What Lies Ahead for Vaccine Development and INO Stock in May? appeared first on InvestorPlace.

What Lies Ahead for Vaccine Development and INO Stock in May?

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares traded lower by 4.1% on Tuesday but remain up 451.5% over the past six months on hopes the company will ultimately be first to market with the COVID-19 vaccine the world desperately needs.

Inovio Option Trader Bets $100K That Coronavirus Vaccine Stock Will Double Again By August

Alpha Pro Tech

Gilead Sciences

Johnson & Johnson

Rite Aid

Teladoc

Teva Pharmaceutical

Several healthcare stocks have jumped higher based off the coronavirus pandemic. But these nine companies have a longer upside pathway.

9 Healthcare Stocks to Buy Even After the Coronavirus Fades

GlaxoSmithKline

Is the high-flying small biotech stock the better choice over the more sluggish big pharma stock?

Better Buy: Inovio Pharmaceuticals vs. GlaxoSmithKline

Among the six coronavirus vaccine candidates that have entered human trials, two belong to publicly listed U.S.

A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio

Mesoblast

The COVID-19 pandemic has been a major catalyst for these three biotech stocks.

Inovio Pharmaceuticals, Mesoblast, and Moderna: Are These Red-Hot Biotech Stocks Still a Buy?

Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates on Sunday said that a vaccine for novel coronavirus (COVID-19) could be produced at a mass-scale within a year.

Bill Gates, Backer of Inovio And Six Others, Says Coronavirus Vaccine Could Be Mass Produced Within A Year

In an interview, Inovio Pharmaceuticals' CEO talked up the company's efforts to develop a COVID-19 vaccine.

Here’s Why Inovio Pharmaceuticals Is Soaring (Again) Today

Sanofi

While the markets have tumbled due to the spread of the novel coronavirus, stocks of pharma companies developing vaccines and treatments for the highly contagious viral infection have fared well. Although vaccine bets still remain quite speculative.

Best Coronavirus Vaccine Stock: Moderna, Inovio, Sanofi Or Johnson & Johnson?

Inovio Pharmaceuticals Inc. (NASDAQ: INO) chief executive officer Joseph Kim told CNBC on Thursday that it's possible to meet the timeline of 12 to 18 months for a novel coronavirus (COVID-19) vaccine suggested by White House Coronavirus Task Force leader member Anthony Fauci.

Inovio CEO Says 'It's Possible' For Coronavirus Vaccine To Be Ready In 12 To 18 Months

"We expect to finish enrollment of all 40 volunteers before the end of April," Inovio CEO Dr. Joseph Kim told CNBC.

Inovio Pharmaceuticals expects to finish recruiting coronavirus vaccine volunteers by the end of April, CEO says

Domino's Pizza

Eli Lilly

Las Vegas Sands

Eli Lilly, Domino's Pizza, Gilead Sciences, Las Vegas Sands and Inovio Pharmaceuticals were our top stock trades for Friday.

5 Top Stock Trades for Friday: GILD, INO, LVS, DPZ, LLY

American Airlines

Aurora Cannabis

Boeing

Carnival

Disney

Ford Motor Company

General Electric

Microsoft

Tesla

Young investors aggressively bought the stock market dip in March, and here are the 10 stocks they bought the most.

10 Hot Stocks That Young Investors Bought Big in March

Here's Why Inovio Pharmaceuticals Jumped 18% Today

These two stocks are kind of like a COVID-19 version of the fable about the tortoise and the hare.

Better Coronavirus Stock: Johnson & Johnson vs. Inovio Pharmaceuticals

Novavax

VBI Vaccines

Investors piled in to COVID-19 vaccine plays today. Here's why.

Why These COVID-19 Vaccine Stocks Soared Today

The major indexes continue to rally. Take advantage by using a bullish position on Inovio Pharmaceuticals, Inc.

Bullish Play on Inovio as it Develops COVID-19 Vaccine

The company will collaborate with the International Vaccine Institute to conduct a phase 1/2 clinical trial for its investigational SARS-CoV-2 vaccine.

Inovio Pharmaceuticals Lands $6.9 Million Grant to Fund a Clinical Trial for Its Coronavirus Vaccine

Shares of Inovio Pharmaceuticals Inc. INO, -4.03% gained 8% in premarket trading on Thursday after the company announced that it had received an additional $6.9 million to fund a Phase 1/2 clinical trial of its COVID-19 vaccine candidate in South Korea.

Inovio's stock jumps on funding for vaccine trial in South Korea

Inovio shares have skyrocketed on the company’s coronavirus work, but short interest shows some investors may be betting on declines.

Is Inovio Pharmaceuticals a Ticking Time Bomb For Investors?

As companies race against time to bring to market a vaccine for the new coronavirus — SARS-CoV-2 — that causes COVID-19, three contenders have emerged as frontrunners, having advanced their candidates into the clinics.

3 Frontrunners In COVID-19 Vaccine Development: What You Need To Know

With phase one of human trials underway, we may be closer than ever to putting the virus to bed. Before that happens, INO stock will run.

INO Stock May Fade After the Virus, but It Could Rocket to $20 First

News for Inovio Pharmaceuticals Stock (INO)